DUBLIN (dpa-AFX) - While reporting financial results for the second quarter on Wednesday, biopharmaceutical company Alkermes plc (ALKS) reiterated its revenue guidance for the full-year 2024.
For fiscal 2024, the company continues to project total revenues between $1.50 billion and $1.60 billion. It also expects net income in a range of $350 million to $390 million and adjusted net income in a range of $465 million to $505 million.
On average, analysts polled by Thomson Reuters expect the company to report revenues of $1.50 billion for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2024 AFX News